From our sex, drugs and rock ‘n’ roll issue, DigitasLBi strategy director David Carr explores the possibilities around 3D printing drugs.
The digital industry has a tendency towards hype. From the obligatory ‘world’s first’ of every award entry, to the buzz around the new, next Facebook whose programmaticmonetising cookies will be around longer than their user base, we are forever announcing the latest paradigm shift.
But some things are worth the hype, and more.
At the beginning of August the FDA announced it had approved Spritam, the first 3D printed pill for use in the human body. Aprecia Pharmaceutical’s new product is actually an off-patent epilepsy drug, but its new MIT-created 3D printing manufacturing method allows for a precise, uniform and high dose in a small tablet.